key: cord-0261010-1df8acfr authors: Gobeil, P. A. M.; Pillet, S.; Boulay, I.; Charland, N.; Lorin, A.; Cheng, M.; Vinh, D.; Boutet, P.; Van Der Most, R.; Roman, F.; de los Angeles Ceregido Perez, M.; D'Aoust, M.-A.; Landry, N.; Ward, B. title: Durability and Cross-Reactivity of Immune Responses Induced by an AS03 Adjuvanted Plant-Based Recombinant Virus-Like Particle Vaccine for COVID-19 date: 2021-08-09 journal: nan DOI: 10.1101/2021.08.04.21261507 sha: 76d0f4c59fbb164e5d46cb4006ec156c06d8153a doc_id: 261010 cord_uid: 1df8acfr As the SARS-COV-2 pandemic evolves, what is expected of vaccines extends beyond efficacy and includes evaluations of both durability and cross-reactivity to emerging variants. To complement an on-going Phase 3 efficacy study, this report expands on previously reported immunogenicity results from a Phase 1 trial of an AS03-adjuvanted, plant-based virus-like particle (VLP) displaying the spike glycoprotein of the Wuhan strain of SARS-CoV-2 virus (NCT04450004). Durability of the humoral and cellular responses against the ancestral strain was evaluated 6 months post-second dose (Day 201) at which time ~94% of vaccinated individuals remained seropositive. Interferon gamma (IFN-{gamma}) and interleukin 4 (IL-4) responses remained detectable in ~94% and ~92% of vaccinated individuals respectively. Cross-reactivity of neutralizing antibodies to Alpha (B.1.17), Beta (B.1.351), and Gamma (P.1) variants of concern (VOC) were also measured. Twenty-one days after the second vaccination, detectable neutralizing antibodies were observed to the Alpha variant by both pseudovirion and wild-type assays for all vaccinated individuals, while 94.7% of individuals had detectable antibodies to the Beta variant in both assays. Neutralizing antibodies to the Gamma variant were detected in 100% and 94.7% of individuals using the pseudovirion and live virus neutralization assays, respectively. In all cases, the vaccine-induced neutralizing GMTs to the VOC 3 weeks post-vaccination were greater than the Wuhan-specific neutralization titers seen in individuals recovered from COVID-19. Coronavirus disease 2019 , the disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has spread rapidly across the globe, infecting Vaccine efficacies reported to date range from ~50-95% 8 and are highly correlated with neutralizing antibody (NAb) titers [9] [10] [11] [12] . The inverse correlation between viral load and NAb titers suggests that antibodies are associated with protection against SARS-CoV-2 and its clinical manifestations 13 . This correlation has also been observed in animal challenge models in which vaccine-generated antibody titers were associated with restricted viral loads and greatly reduce lung inflammation 14, 15 . Furthermore, the transfer of antibodies from convalescent animals to naïve animals 16 or between humans in a clinical setting 17, 18 can, in some circumstances, result in clinical . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 9, 2021. ; https://doi.org/10.1101/2021.08.04.21261507 doi: medRxiv preprint improvement , decline in viral loads, and reduced mortality. Cell-mediated immunity has also been shown to be involved in both protection against disease and in the establishment of long-lasting immunity [19] [20] [21] . The continued presence of circulating antibodies and cell-mediated immune responses may indicate durable protection. After infection, NAb titers decline gradually after the initial peak and remain detectable for minimally 8 months 22, 23 . Data involving vaccineinduced humoral immunity suggests a similar pattern with half-lives varying depending on the model used 24, 25 . In addition to antibodies, lasting cellular memory responses were observed in the periphery of individuals previously infected with SARS-CoV-2 and are expected to contribute to durability of protection 26, 27 . Potential reinfection with SARS-CoV-2 depends on both durability of the immune response and cross-reactivity against emerging variants in circulation, which may have several competitive advantages against established strains with respect to enhanced replication, transmission, or escape from immune system responses 28, 29 . As established immunity may provide variable protection against variants of concern (VOC) 30, 31 and existing antibodies provide variable cross-reactivity 32 , there is a clear need to assess NAbs titers induced by different vaccines and vaccine candidates against new variants. As many countries move from a primary pandemic response to a sustained endemic response, the durability and breadth of protection induced by vaccines become increasing concerns. This report expands on the previously described phase 1 study evaluating a plant-based virus-like particle displaying SARS-CoV-2 spike glycoprotein . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted August 9, 2021. ; https://doi.org/10.1101/2021.08.04.21261507 doi: medRxiv preprint (CoVLP) adjuvanted with AS03 33 by investigating the durability of antibody and cellmediated immune responses as well as the cross-reactivity of vaccine-induced NAbs against Alpha, Beta, and Gamma VOC 34 . Samples from a subgroup of 20 healthy individuals with a median age of 36 years (range 19-49 years) who received two doses of vaccine made of 3.75 µg CoVLP adjuvanted with AS03 (CoVLP+AS03) 21 days apart were analyzed 21 days after each vaccination (Days 21, 42) and 6 months after the second vaccination (Day 201) and the data are presented in this report. Demographics are detailed in Table 1 . A panel of human convalescent sera/plasma (HCS) from patients recovering from mild, moderate, or severe COVID-19 infection is included for comparison. This report is focusing on the durability of the responses measured at Day 201 as humoral and cell-mediated immune responses elicited 21 and 42 days after immunization were previously reported and discussed 33 . To evaluate the durability of the humoral response, the anti-spike immunoglobulin G (IgG) enzyme-linked immunosorbent assays (ELISA), pseudovirion neutralization assays (PNA), and live-virus microneutralization assays (MNA) were used, as previously described 33 (Figure 1 ). . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted August 9, 2021. Figure 1c ). WHO mixed . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted August 9, 2021. Overall, these data show that two doses of the CoVLP+AS03 vaccine elicited binding antibodies and NAbs that remained detectable 6 month after the second vaccination in ~95% of individuals. Antibody titers at that late timepoint were comparable to those of patients recovering from natural COVID-19 infection. The cell-mediated immune (CMI) response and associated Th1/Th2 balance was evaluated by expression of IFN-γ (Th1) and IL-4 (Th2) cytokine ELISpot on PBMC upon ex-vivo antigen recall using a SARS-CoV-2 spike-derived peptide pool (Wuhan strain). At Day 201, almost all participants had a readily detectable IFN-γ response (17/18; . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted August 9, 2021. As expected, pre-vaccination sera were not reactive to the spike proteins of SARS-CoV-2, SARS-CoV-1, or MERS. Sera from subjects vaccinated with CoVLP+AS03 and patients recovering from COVID-19 were highly reactive to the SARS-CoV-2 spike protein in this assay. Antibody binding for vaccinated individuals were approximately . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 9, 2021. ; https://doi.org/10.1101/2021.08.04.21261507 doi: medRxiv preprint one order of magnitude higher than for individuals in the HCS group (p<0.0001). Although the binding of vaccinated and HCS sera to the SARS-CoV-1 spike protein was lower than to the SARS-CoV-2 spike protein, sera from vaccinated individuals still had significantly higher binding to the SARS-CoV-1 spike protein than HCS (p<0.0001). Neither vaccination nor infection with SARS-CoV-2 induced statistically significant cross-reactive antibodies to the MERS spike protein ( Figure 3 ) or spike proteins from common cold coronaviruses (Supplementary Figure 1) . The cross-reactivity of antibodies induced by CoVLP+AS03 at Day 42 ( . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 9, 2021. Taken together, these data show that 2 doses of the CoVLP+AS03 vaccine given 3 weeks apart induced an antibody response that retained detectable neutralizing crossreactivity to the Alpha, Beta, and Gamma variants in the vast majority (~95%) of subjects and which remained comparable to or better than levels seen with HCS against the ancestral strain. . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 9, 2021. ; https://doi.org/10.1101/2021.08.04.21261507 doi: medRxiv preprint This report expands on a Phase 1 immunogenicity and tolerability study in which immunogenicity of CoVLP without adjuvant was compared to CoVLP+AS03 or CoVLP adjuvanted with CpG1018 and CoVLP doses of 3.75, 7.5 or 15.0 µg were compared 36 by CoVLP+AS03, the current analysis nevertheless provides confidence regarding the durability of the humoral response and illustrates that, even 6 months after the second vaccination, the vaccine-induced antibody response is comparable to that seen after natural COVID-19 infection. . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 9, 2021. ; https://doi.org/10.1101/2021.08.04.21261507 doi: medRxiv preprint Consistent with previous reports 23 While the role of IFN-γ and Th1-type response play a critical role in protection against viral infection including coronaviruses [44] [45] [46] [47] [48] , IL-4 is associated with a Th2-type response which in turn has been associated with both protective immunity and concerns involving vaccine-associated enhanced disease. This was a concern during early coronavirus vaccine development 49, 50 , and it is considered an important potential risk for SARS-CoV-2 vaccines. Assessment of the Th1/Th2 polarization of immune responses in the context of VAED was therefore considered critical 51, 52 . To date however, no VAED has been observed with any SARS-CoV-2 vaccine, including the CoVLP vaccine candidate 33, 53 . In the development program of CoVLP vaccine candidate specifically, cumulative clinical data up to phase 2 and experimental non-human primate data have not revealed any sign of VAED associated with CoVLP with or without an adjuvant despite the induction of both Th1-and Th2-type cytokines 15, 33, 37 . In fact, the IL-4 response elicited by CoVLP+AS03 may play an important role in supporting strong antibody responses, . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 9, 2021. ; https://doi.org/10.1101/2021.08.04.21261507 doi: medRxiv preprint potentially by supporting follicular T-cell involvement and germinal center development 40, [54] [55] [56] . Indeed, AS03 administered with other antigens has been shown to promote durable humoral response 57, 58 . Herein, the capacity of the vaccine-induced antibodies to cross-react to spike proteins from SARS-CoV-2, MERS, and common human coronaviruses was tested. Antibodies induced by natural infection may cross-react with spike conformational epitopes 59 . CoVLP+AS03 induced antibodies with cross-reactivity to viral spike proteins of SARS-CoV-1 but not MERS or common cold coronaviruses. For the purposes of examining the cross-reactivity to Alpha, Beta, and Gamma VOC, this report has adopted the methodology proposed by others 31 is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 9, 2021. ; https://doi.org/10.1101/2021.08.04.21261507 doi: medRxiv preprint broader perspective across the vaccine development landscape, it is worth considering the work of Oliver who recently presented a meta-analysis of vaccine-induced antibody neutralization of variants 32 . Based on this analysis, differential responses (ie: foldchange versus the Wuhan response) to variants are relatively consistent across vaccine platform and differences in cross-reactivity between specific vaccines are largely attributable to the scale of absolute neutralizing antibody titers elicited. Comparing to CoVLP+AS03, the-fold-change in antibody neutralization across the VOC tested was overall comparable to what has been reported for other vaccines 32 . These observations reinforce the importance of considering cross-reactivity based on a tiered approach or as a proportion of vaccinees with detectable neutralizing antibodies. Importantly, the analysis presented here does not include data for the Delta or Lambda variants of increasing global concern. Investigating the cross-reactivity of antibodies generated by CoVLP+AS03 to these variants is of significant interest and is underway. Vaccines inducing immune responses with strong variant cross-reactivity and long durability have the potential to provide protection against infection when deployed either as part of a primary pandemic response or as part of an ongoing vaccination strategy to eventually address endemic COVID-19. The data for CoVLP+AS03 presented herein demonstrate that this vaccine can induce a durable immune response against SARS-CoV-2 with broad cross-reactivity to several of the emerging VOCs. While the durability and cross-reactivity data presented herein are promising, a large Phase 3 trial ongoing in several countries with active circulation of multiple VOCs will likely provide insight into the implications of these observations for the efficacy of CoVLP+AS03. . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 9, 2021. ; https://doi.org/10.1101/2021.08.04.21261507 doi: medRxiv preprint The CoVLP vaccine candidate has previously been described in detail 33 . Briefly, fulllength spike protein from SARS-CoV-2 (strain hCoV-19/USA/CA2/2020) incorporating the modifications R667G, R668S, R670S, K971P, and V972P is expressed in Nicotiana benthamiana by transient transfection, resulting in spontaneous trimer formation, VLP assembly and budding. The purified CoVLP is mixed with AS03 immediately prior to injection. The AS03 adjuvant is an oil-in-water emulsion containing DL-α-tocopherol (11.69 mg/dose) and squalene (10.86 mg/dose) and was supplied by GlaxoSmithKline. The Phase 1 study design investigating tolerability and immunogenicity of CoVLP with and without adjuvants was previously described 33 . Ethical approved was provided by the Advarra Institutional Review Board as well as the Health Products and Food Branch of Health Canada and the study was carried out in accordance with the Declaration of Helsinki and the principles of Good Clinical Practices. Participants were recruited from existing databases of volunteers, and written informed consent was obtained from all study participants before any study procedure. Participants were offered modest compensation for their participation in this study (that is, time off work and displacement costs). . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 9, 2021. ; https://doi.org/10.1101/2021.08.04.21261507 doi: medRxiv preprint This ELISA measured binding to SARS-Cov2 S protein in its prefusion configuration (SARS-Cov2/Wuhan/2019, Immune Technology Corp.: amino acids 1-1208 with the furin site removed and no transmembrane region) as previously described 33 . Pseudovirion neutralizing antibody analysis was performed using a genetically modified Vesicular Stomatitis Virus (VSV) engineered to express the SARS-CoV-2 S glycoprotein (NXL137-1 in POG2 containing 2019-nCOV Wuhan-Hu-1; Genebank: MN908947) from which the last nineteen amino acids of the cytoplasmic tail were removed (rVSVΔG-Luc-Spike ΔCT) (Nexelis, Quebec, Canada) as previously described 33 . Cross-reactivity to variants was tested using modified pseudovirion expressing SARS- . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 9, 2021. ; https://doi.org/10.1101/2021.08.04.21261507 doi: medRxiv preprint Neutralizing antibody analysis was performed using a cell-based cytopathic effect assay (VisMederi, Sienna, Italy) based on ancestral SARS-Co-2 virus (2019 nCOV ITALY/INMI1, provided by EVAg; Genebank: MT066156) as previously described 33 . For cross-reactivity against variants, the assay was conducted with Alpha (swab isolate As previously described 37 is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 9, 2021. ; https://doi.org/10.1101/2021.08.04.21261507 doi: medRxiv preprint hence a normalization factor of 0.91 was applied to the MNA titers to allow expression in IU/mL. Antibody t½ were calculated by exponential decay model based on values observed at Day 42 and Day 201. The mean of the individually calculated t½ values were reported along with 95% confidence intervals (CI). GraphPad Prism software was used to calculate means and 95% CIs. Cross-reactivity to SARS, MERS and common cold coronaviruses was quantified using the VaxArray platform and the Coronavirus SeroAssay at InDevR, Inc. (Boulder, CO). Spike protein antigens representing full-length spike, receptor binding domain (RBD), and the S2 extracellular domain of SARS-CoV-2, and the spike proteins from SARS, MERS, HKU1, OC43, NL63, and 229E were printed on the microplates. Prior to use, the microarray slides were equilibrated to room temperature for 30 minutes. All serum samples were diluted at 100-fold and a predetermined subset of 20 samples were diluted at 1000-fold in Protein Blocking Buffer (PBB) and applied to the microarray and allowed to incubate in a humidity chamber on an orbital shaker at 80 rpm for 60 minutes. After incubation, the samples were removed using an 8-channel pipette and the slides were subsequently washed by applying 50uL of Wash Buffer 1. . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 9, 2021. ; https://doi.org/10.1101/2021.08.04.21261507 doi: medRxiv preprint Slides were washed for 5 minutes on an orbital shaker at 80 RPM after which the wash solution was removed. Anti-human IgG Label (VXCV-7623) was prepared by diluting the label to 1:10 in PBB after which 50uL of label mixture was added to each array. Detection label was incubated on the slides in the humidity chamber for 30 minutes before subsequent, sequential washing in Wash Buffer 1, Wash Buffer 2, 70% Ethanol, and finally ultrapure water. Slides were dried using a compressed air pump system and imaged using the VaxArray Imaging System (VX-6000). The slides were imaged at a 100 ms exposure time. The raw signal was converted to signal to background ratio and reported as arbitrary relative binding units. PBMC samples from study subjects were analyzed by IFN-γ or IL-4 ELISpot (Caprion, Quebec, Canada) using a pool of 15-mer peptides with 11aa overlaps from SARS-CoV-2 S protein (USA-CA2/2020, Genbank: MN994468.1, Genscript, purity >90%). Full details of the methodology are detailed elsewhere 33 . Medicago Inc. is committed to providing access to anonymized data collected during the trial that underlie the results reported in this article, at the end of the clinical trial, which is currently scheduled to be 1 year after the last participant is enrolled, unless granted an extension. Medicago Inc. will collaborate with its partners (GlaxoSmithKline, Rixensart, Belgium) on such requests before disclosure. Proposals should be directed to wardb@medicago.com or daoustma@medicago.com. To gain access, data requestors will need to sign a data access agreement and access will be granted for non-commercial research purposes only. . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 9, 2021. ; https://doi.org/10.1101/2021.08.04.21261507 doi: medRxiv preprint Black triangles indicate immunization. Significant differences between timepoints are indicated by asterisk(s) (*p<0.05; ****p<0.0001. One-way analysis of variance using a mixed-effect model on log-transformed data GraphPad Prism, v9.0). is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 9, 2021. ; https://doi.org/10.1101/2021.08.04.21261507 doi: medRxiv preprint indicate 95% CI. Significant differences between timepoints are indicated by asterisk(s) (*p<0.05; **p<0.01; ***p<0.001; ****p<0.0001 Friedman test followed by Dunn's comparisons test, GraphPad Prism, v9.0.1). . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted August 9, 2021. ; https://doi.org/10.1101/2021.08.04.21261507 doi: medRxiv preprint Table Table 1 : Summary demographics and baseline characteristics of the trial subgroup of participants who received 3.75 µg CoVLP adjuvanted with AS03 (NCT04450004) and patients convalescing from COVID-19. CoVLP, plant-produced virus-like particle; SD, standard deviation. . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted August 9, 2021. ; https://doi.org/10.1101/2021.08.04.21261507 doi: medRxiv preprint Figure 1 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted August 9, 2021. ; https://doi.org/10.1101/2021.08.04.21261507 doi: medRxiv preprint . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted August 9, 2021. ; https://doi.org/10.1101/2021.08.04.21261507 doi: medRxiv preprint . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted August 9, 2021. ; https://doi.org/10.1101/2021.08.04.21261507 doi: medRxiv preprint . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted August 9, 2021. ; https://doi.org/10.1101/2021.08.04.21261507 doi: medRxiv preprint Supplemental Figure . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted August 9, 2021. ; https://doi.org/10.1101/2021.08.04.21261507 doi: medRxiv preprint COVID-19 CORONAVIRUS PANDEMIC Severe Covid-19 The COVID-19 puzzle: deciphering pathophysiology and phenotypes of a new disease entity Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data Immunological considerations for COVID-19 vaccine strategies Regulatory Focus: COVID-19 vaccine tracker World Health Organization. The COVID-19 candidate vaccine landscape and tracker Target Product Profile Analysis of COVID-19 Vaccines in Phase III Clinical Trials and Beyond: An Early 2021 Perspective Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection Evidence for antibody as a protective correlate for COVID-19 vaccines. medRxiv What level of neutralising antibody protects from COVID-19? medRxiv A public vaccine-induced human antibody protects against SARS-CoV-2 and emerging variants DNA vaccine protection against SARS-CoV-2 in rhesus macaques Immune Correlates of Protection by mRNA-1273 Immunization against SARS-CoV-2 Infection in Nonhuman Primates. bioRxiv Safety, immunogenicity and protection provided by unadjuvanted and adjuvanted formulations of recombinant plant-derived virus-like particle vaccine candidate for COVID-19 in non-human primates. bioRxiv Correlates of protection against SARS-CoV-2 in rhesus macaques Deployment of convalescent plasma for the prevention and treatment of COVID-19 Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three-Month Experience. medRxiv Early T cell and binding antibody responses are associated with Covid-19 RNA vaccine efficacy onset Early induction of functional SARS-CoV-2-specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients Robust SARS-CoV-2-specific T cell immunity is maintained at 6 months following primary infection Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection Antibody titers against SARS-CoV-2 decline, but do not disappear for several months Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19 Tolerability and Immunogenicity After a Late Second Dose or a Third Dose of ChAdOx1 nCoV-19 (AZD1222) Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection Functional responsiveness of memory T cells from COVID-19 patients Genetic Variants of SARS-CoV-2-What Do They Mean? Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies Changes in symptomatology, reinfection, and transmissibility associated with the SARS-CoV-2 variant B.1.1.7: an ecological study Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant Overview of data to inform recommendations for booster doses of COVID-19 vaccines Phase 1 randomized trial of a plant-derived virus-like particle vaccine for COVID-19 Tracking SARS-CoV-2 Variants SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma Human antibody response to N-glycans present on plant-made influenza viruslike particle (VLP) vaccines Interim Report of a Phase 2 Randomized Trial of a Plant-Produced Virus-Like Particle Vaccine for Covid-19 in Healthy Adults Aged 18-64 and Older Adults Aged 65 and Older. medRxiv Dynamics of Neutralizing Antibody Titers in the Months After Severe Acute Respiratory Syndrome Coronavirus 2 Infection Persistence of functional memory B cells recognizing SARS-CoV-2 variants despite loss of specific IgG. medRxiv SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses Establishment of the WHO International Standard and Reference Panel for anti-SARS-CoV-2 antibody. (World Health Organization Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. medRxiv Longitudinal characterization of humoral and cellular immunity in hospitalized COVID-19 patients reveal immune persistence up to 9 months after infection. bioRxiv T cell vaccines for microbial infections Revealing the role of CD4(+) T cells in viral immunity Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19 The Dual Nature of Type I and Type II Interferons Direct Antiviral Mechanisms of Interferon-Gamma Severe acute respiratory syndrome-associated coronavirus vaccines formulated with delta inulin adjuvants provide enhanced protection while ameliorating lung eosinophilic immunopathology Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus Consensus summary report for CEPI/BC March 12-13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines Vaccine-associated enhanced disease: Case definition and guidelines for data collection, analysis, and presentation of immunization safety data SARS-CoV-2 Vaccine Development: Current Status Follicular helper CD4 T cells (TFH) Tuning the Cytokine Responses: An Update on Interleukin (IL)-4 and IL-13 Receptor Complexes Can follicular helper T cells be targeted to improve vaccine efficacy? F1000Res Adjuvanted H5N1 influenza vaccine enhances both cross-reactive memory B cell and strain-specific naive B cell responses in humans An observer-blind, randomized, multicenter trial assessing long-term safety and immunogenicity of AS03-adjuvanted or unadjuvanted H1N1/2009 influenza vaccines in children 10-17 years of age SARS-CoV-2 antibodies remain detectable 12 months after infection and antibody magnitude is associated with age and COVID-19 severity. medRxiv Sera neutralizing activities against SARS-CoV-2 and multiple variants six month after hospitalization for COVID-19 Neutralizing Activity of BNT162b2-Elicited Serum Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7 The authors wish to acknowledge all the Medicago employees, their contractors and all the volunteers who participated in the study as well as the site investigators and their staff who conducted the studies with a high degree of professionalism. The study was sponsored by Medicago Inc. All authors contributed significantly to the submitted work. BJ Ward and N Landry contributed to all aspects of the clinical study from conception to completion. P Gobeil,